Masitinib for the Treatment of Severe Mast Cell Activation Syndrome
Status:
Recruiting
Trial end date:
2024-12-31
Target enrollment:
Participant gender:
Summary
To evaluate the efficacy and safety of two dosing schemes of oral masitinib versus matching
placebo in the treatment of patients suffering from severe MCAS with handicap unresponsive to
optimal symptomatic treatment.